Dislipidemia treatment with original and generic statins: clinical and cost-effect efficacy, safety

Abstract

Aim. To compare clinical, cost-effect efficacies and safety of simvastatin Zokor and generic Vasilip in correction of dislipoproteinemia in patients with ischemic heart disease. Material and methods. The original statin Zokor and generic statin Vasilip were given for 8 weeks in a dose 20 mg/day. Results. Vasilip and Zokor demonstrated similar hypolipidemic efficacy and safety, but Vasilip administration was more cost-effective. Conclusion. Simvastatin Vasilip is recommended for wider use in clinical practice because it is clinically and cost effective.

Keywords

• dislipidemia
• simvastatins
• generic drugs
• cost-effect assessment